

# Supporting Information

Ehre et al. 10.1073/pnas.1206552109

## SI Materials and Methods

**Muc5ac-GFP cDNA Cloning and Transfection.** Muc5ac genomic regions corresponding to exons 1–31 (19,200 bp) and exons 31–49 (9,714 bp) were available through GenBank under accession numbers AJ511870 and AJ511871. Computer analysis predicted the location of all 49 exons, which allowed generation of a Muc5ac cDNA template and primer design that included the Kozack consensus sequence/start codon and the stop codon. mRNAs were extracted from C57BL/6J mouse lungs and reverse transcribed. Muc5ac cDNA was cloned into three fragments [5' end, variable number of tandem repeats (VNTR), and 3' end], using high-fidelity polymerases (Herculase DNA polymerase; Stratagene). Clone assembly to generate the full-length cDNA was achieved via unique restriction sites and ligation. GFP tagging was performed internally, immediately 5' of the VNTR, by use of enzyme digestion and ligation. Mutagenesis was performed to introduce glycine and alanine residues at each end of the GFP insert to allow proper protein folding. Full sequencing of the GFP-tagged cDNA confirmed that no random mutations occurred during cloning and verified proper insert direction. The Muc5ac-GFP fusion protein was cloned into the expression cassette consisting of the rat CCSP promoter (1) in a pTG1 plasmid (2) [University of North Carolina (UNC) Animal Model Core] that was successfully used for another model (3). TG1-rCCSP-Muc5ac/GFP (15 kb) was used to transfect 293T cells via lipofectamine as described by the manufacturer (Invitrogen), and positive cells were identified 48 h after transfection via fluorescence microscopy.

**Generation of Transgenic Animals and Real-Time RT-PCR.** All mouse studies were approved by the UNC Institutional Animal Care and Use Committee. Transgenic mice with airway-specific overexpression of Muc5ac-GFP were generated by microinjection of fertilized C57BL/6 oocytes with the expression cassette pTG1-rCCSP-Muc5ac/GFP. Founder animals were bred with C57BL/6 mice, producing independent lines of Muc5ac-GFP transgenic mice. Transgene-positive animals were identified by PCR for GFP expression. All studies reported in this article were conducted with a single transgenic mouse line that showed the highest level of transgene expression. WT littermates served as controls. We monitored animal weight from birth to adult stage and detected no significant differences between transgenic and WT littermate controls. Mice were housed in a pathogen-free animal facility and had free access to chow and water. Total lung mRNAs were harvested from whole lung homogenates, including trachea. For proximal vs. distal airway analyses (which excluded the trachea), each lung lobe was dissected by a median cross-section, separating proximal from distal regions before homogenization. Real-time PCR analysis from reverse-transcribed RNA (RNeasy kit; Qiagen) was conducted using a Roche LightCycler. Specific primers were designed to detect endogenous and exogenous Muc5ac simultaneously (shown in Fig. S1) and specific primers were designed to detect Muc5b (Fwd-CTGGCACCTGCTCTGTGCA and Rev-CACTGCTTTGAGGCAGTTCT). mRNA primers (18S) were used for expression normalization. The fold increase of mucin mRNA expression was determined by crossing-point analysis and standard curves (LightCycler Software version 3.5; Roche).

**Bronchoalveolar Lavage and Inflammatory Cell Counts.** Bronchoalveolar lavage (BAL) was performed to collect fluid and quantify mucin, lung inflammatory cells, and virus titers as previously described (4). Briefly, mice were euthanized with CO<sub>2</sub> and tracheas cannulated with a blunt 20-gauge needle via an

incision. Whole lungs were lavaged once with 30  $\mu\text{L}/\text{g}^{-1}$  body weight of PBS. Collected BAL samples were processed dependent on the proposed experiment, to detect either protein expression or inflammatory cell counts. For cell counts, BAL cells were pelleted by centrifugation at 1,000  $\times g$  for 5 min at 4  $^{\circ}\text{C}$ , cells resuspended in 100  $\mu\text{L}$  of PBS, and total cells counted with a hemocytometer. Cytospin slides of 30,000–60,000 cells per slide were obtained (StatSpin CytoFuge 2), air dried, and stained with modified Giemsa for differential cell counts (Newcomer Supply) of at least 200 cells per slide.

**Antibodies and Western Blotting.** Western blotting and immunohistochemistry for GFP and CCSP expression used a goat polyclonal anti-GFP antibody (Rockland), a rabbit polyclonal anti-GFP antibody (Abcam), and a goat anti-CCSP antibody (Santa Cruz). Rabbit polyclonal antibodies to Muc5b (UNC222) (5) and Muc5ac (UNC294) were generated by immunizing rabbits with synthetic peptides corresponding to unique peptide sequences (CQPQCQWTKWIDVDY and HYITFDGQRYSFNGD, respectively). Antibody specificity was demonstrated by peptide BLAST and Western blotting, as shown in Fig. 3. To assess the expression of Muc5ac-GFP in transgenic animals, BAL was used to harvest lung secretions. Briefly, equal amounts of bronchoalveolar lavage fluid (BALF) samples (40  $\mu\text{L}$ ) were loaded into an agarose gel (0.8%) under native or reducing conditions (10 mM DTT for 5 min at 70  $^{\circ}\text{C}$ ). BALF mucins were resolved by electrophoresis (80 V, 90 min) and transferred by vacuum blotting (VacuGene XL; GE Healthcare) to nitrocellulose membranes. Blots were probed with Muc5ac, Muc5b, and/or GFP antibodies. Despite pooling and concentrating BALF from several WT animals, the endogenous Muc5ac signal was weak with an elevated background, limiting studies in WT mice with the available biological tools. IRDye secondary antibody fluorescence was detected with a Li-Cor Odyssey Infrared Imaging System. Detection of sialic acid residues used the biotinylated anti-lectins, maackia amurensis (MAA) and elderberry bark (SNA) for  $\alpha$ 2,3- and  $\alpha$ 2,6-linked sialic acids (Vector Laboratories), respectively, a goat anti-biotin antibody (Vector Laboratories) and a donkey anti-goat antibody labeled with IRDye (Licor).

**HPLC and Refractometry/Light Scattering and Density Gradient.** Pooled mouse BALF was run through a size-exclusion S1000 column, collecting the void into 0.5-mL aliquots (as described in ref. 6). A light-scattering detector and a reflective index detector connected to a Dawn program and a MALLS system were used to monitor the constituents of each fraction, thus providing data on molecular weight (absolute molecular size and mass distribution) and radius of gyration/compactness. Fractions obtained by gel permeation chromatography were subjected to slot-blotting and either stained with alcian blue periodic acid–Schiff (AB-PAS) to determine glycoprotein-rich fractions or immunoblotted. For CsCl density gradient experiments, CsCl was added to pooled BALF samples and placed into 10-mL ultracentrifugation tubes (as described in ref. 7). Centrifugation was performed for 48 h, tubes were reopened, and  $\sim$ 1-mL aliquots were carefully collected from the top to the bottom of the tube without disturbing the layered solution. In this technique, sedimentation depends on the surface-to-mass ratio. Fractions were subjected to AB-PAS staining and immunodetection.

**Tissue Histology.** Lungs fixed in 10% (vol/vol) neutral buffered formalin and embedded in paraffin were prepared as histological sections. After deparaffinization, sections were stained with hematoxylin and eosin (H&E) or AB-PAS or blocked for 1 h in 3% BSA, before

immunohistochemistry was performed. Primary antibody (goat anti-GFP) was applied overnight, followed by a secondary antibody (anti-goat Alexa Fluor 488). Slides were mounted with an antifade, DAPI medium (Vectashield; Vector Laboratories). Fluorescence was detected with a Leica SP2 laser scanning confocal microscope, using 20X/0.4 air, or an Achromatic Plan  $\times 63/1.4$  oil-immersion objective lens. For studies of mucus layer morphology, lungs were fixed with 1% osmium tetroxide in perfluorocarbon ( $\text{OsO}_4/\text{PFC}$ ; FC-72) (8) and embedded in epon resin, and sections were prepared for electron microscopy. For frozen sections, lung tissue specimens were embedded in OCT (Cryo Embedding Medium) and rapidly frozen on dry ice before performing cryosections with a microtome. For fresh tissue preparation, tracheas were embedded in a low-melting temperature agarose, sectioned with a vibratome, and transferred to histology slides.

**Ovalbumin Sensitization.** Airway mucus metaplasia was induced in mice via ovalbumin (OVA) sensitization and challenge, using a procedure detailed previously (9). Briefly, OVA was injected i.p. into each mouse on days 0, 7, and 14. On days 21 and 24, 50  $\mu\text{L}$  of 2.0% OVA in PBS was instilled by aspiration into tracheas of isoflurane-anesthetized mice. The instillation procedure was completed in  $<20$  s; recovery from the procedure was 100%. Experimental procedures were performed 2–3 d following the second OVA instillation.

**Mucociliary Clearance Measurement.** To measure mucociliary transport in the trachea (as described in ref. 10), mice were anesthetized with a mixture of ketamine/xylazine (90 and 10 mg/kg body weight, respectively) and placed on a heated pad, and a rectal temperature probe was inserted to monitor body temperature. The trachea was surgically exposed (not opened) and a drop of water-equilibrated mineral oil was placed on the exterior of the trachea to prevent desiccation. Then a 15- $\mu\text{L}$  suspension of 3  $\mu\text{m}$  fluorescent beads (Polysciences) (prepared by adding 10  $\mu\text{L}$  stock beads to 2  $\mu\text{L}$  egg white and 99  $\mu\text{L}$  distilled water) was injected into the mouse's nose. Sufficient beads were aspirated for visualization through the exposed trachea. The mouse was positioned with the head elevated  $\sim 10^\circ$  and tracheal transport of fluorescent beads was recorded using a Leica MZ 16FA fluorescent dissecting microscope and a digital camera interfaced to a DVD recorder. The rate of MCC was determined by measuring the time required for fluorescent beads to move a measured distance by an investigator blinded to the animal's genotype. Usually, 5–10 particles were tracked for each animal and the average was taken as the rate of MCC. After MCC was measured on the anesthetized mouse, the mouse was killed by exsanguination (aorta sectioning) and the MCC measurements were repeated. Results are presented as an average of live and dead animals.

**Viral Infection and Titer.** The influenza virus A/PR/8/34 (H1N1) (Reading) has been extensively characterized as in refs. 11 and 12. In brief, as assessed by sequencing and sequence alignment, this A/PR/8/34 (H1N1) (Reading) exhibited a lineage consistent with

the Mount Sinai lineage and was shown biochemically to preferentially bind  $\alpha 2,3$ -sialic acid. This PR8 virus was propagated on Madin–Darby Canine Kidney (MDCK) cells. Mice were briefly anesthetized with isoflurane and inoculated with 700 pfu of influenza virus via the intranasal route in 20  $\mu\text{L}$  of PBS. Mice were weighed daily and assessed for visual signs of clinical disease, including inactivity, ruffled fur, labored breathing, and huddling behavior. At specific times after inoculation (day 2 and day 4), mice were euthanized, the lungs harvested, and the right lower lobes homogenized for virus titers, and the left lobe was fixed for histology studies. Virus titers were determined by standard plaque assay on MDCK cells, as previously described (13). These experiments were performed in three litters in separate experiments at three designated time points. A total number of 18 mice were inoculated for in vivo measurement of infection as determined by viral titers.


For inflammatory response analysis, a total of 10 mice were inoculated in independent experiments. Inoculation occurred as described above. Mice were euthanized and lungs were lavaged at day 2 p.i. For BALF cell counts, see *Bronchoalveolar Lavage and Inflammatory Cell Counts*.

To determine whether BALF or purified mucins neutralized influenza virus infection, virus was incubated directly with BALF or purified Muc5ac and plaque assays were performed. WT and Muc5ac-transgenic (Muc5ac-Tg) BALFs were collected from 10 different animals for each group and pooled, reaching a total protein concentration of 1 mg/mL. BALF pools were UV treated for sterilization. Purified Muc5ac was obtained from BALF pooled from 10 Muc5ac-Tg animals. The BALF pool was treated with 6 M guanidine to dissociate small globular proteins and Muc5ac was purified by a CsCl density gradient, detecting Muc5ac-rich fractions by slot blot. Briefly, influenza virus stocks were diluted to  $10^4$  plaque-forming units (pfu)/mL in PBS. Diluted virus (100  $\mu\text{L}$ ) was mixed with 100  $\mu\text{L}$  of PBS alone, PBS + BSA (2 mg/mL), WT BALF (1 mg/mL), Muc5ac-Tg BALF (1 mg/mL), or purified Muc5ac (2 mg/mL) and incubated at room temperature for 20 min. Each mixture was then serially diluted (10-fold dilutions) in serum-free DMEM and applied to MDCK cell monolayers for 1 h at 37  $^\circ\text{C}$ . The inoculum was then removed, and cells were treated with 2% agar-based overlay medium. Three days following overlay, MDCK cells were fixed and stained with crystal violet to visualize and quantitate plaques.

The same technique was applied for BALF treated with neuraminidase. BALFs were treated for 1 h at 37  $^\circ\text{C}$  with neuraminidase (150 milliunits/mL). Neuraminidase was deactivated by heat at 60  $^\circ\text{C}$  for 5 min before incubation with the virus. Treated and untreated BALFs were incubated at room temperature for 20 min with the virus and applied in serial dilutions to MDCK cells (as described above).

**Statistical Analyses.** Results are expressed as means  $\pm$  SEM. Statistical analyses were performed using *t* tests or GraphPad Prism 4.0 for survival curves. A *P* value of  $<0.05$  was considered as the minimum acceptable probability for the difference between the means.

- Hackett BP, Gitlin JD (1992) Cell-specific expression of a Clara cell secretory protein-human growth hormone gene in the bronchiolar epithelium of transgenic mice. *Proc Natl Acad Sci USA* 89:9079–9083.
- Ostrowski LE, Hutchins JR, Zakei K, O'Neal WK (2003) Targeting expression of a transgene to the airway surface epithelium using a ciliated cell-specific promoter. *Mol Ther* 8:637–645.
- Mall M, Grubb BR, Harkema JR, O'Neal WK, Boucher RC (2004) Increased airway epithelial Na<sup>+</sup> absorption produces cystic fibrosis-like lung disease in mice. *Nat Med* 10:487–493.
- Zhu Y, et al. (2008) Munc13-2<sup>-/-</sup> baseline secretion defect reveals source of oligomeric mucins in mouse airways. *J Physiol* 586:1977–1992.
- Nguyen LP, et al. (2008) Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. *Am J Respir Cell Mol Biol* 38:256–262.
- Kesimer M, Sheehan JK (2008) Analyzing the functions of large glycoconjugates through the dissipative properties of their absorbed layers using the gel-forming mucin MUC5B as an example. *Glycobiology* 18:463–472.
- Sheehan JK, et al. (2000) Physical characterization of the MUC5AC mucin: A highly oligomeric glycoprotein whether isolated from cell culture or in vivo from respiratory mucous secretions. *Biochem J* 347:37–44.
- Sims DE, Horne MM (1997) Heterogeneity of the composition and thickness of tracheal mucus in rats. *Am J Physiol* 273:L1036–L1041.
- Evans CM, et al. (2004) Mucin is produced by clara cells in the proximal airways of antigen-challenged mice. *Am J Respir Cell Mol Biol* 31:382–394.
- Ostrowski LE, et al. (2010) Conditional deletion of dnac1 in a murine model of primary ciliary dyskinesia causes chronic rhinosinusitis. *Am J Respir Cell Mol Biol* 43:55–63.
- Elleman CJ, Barclay WS (2004) The M1 matrix protein controls the filamentous phenotype of influenza A virus. *Virology* 321:144–153.
- Meng B, Marriott AC, Dimmock NJ (2010) The receptor preference of influenza viruses. *Influenza Other Respir Viruses* 4:147–153.
- Lorsbach RB, Russell SW (1992) A specific sequence of stimulation is required to induce synthesis of the antimicrobial molecule nitric oxide by mouse macrophages. *Infect Immun* 60:2133–2135.



TT GCTCCACAGC

1    **ATGGGTG**TCG CCGCGAGAAA GTTGGTCCCA TTCTGGTCC TAGCCCTGGC CCTGGCCTGC AGCCAATGCA CAGGCCAGGC TCAACAGGAC TCTCTGAAAT

101 CGTACCATGA ACACCGCTCT GATGTTCTCC ACCCTCAAGG GCATGTTGGT ACCCACTCA ATAGGGTGAC CATCATCCCA CCTCTGAAGA CCATCCCTGT

201 GGTAGCAGCC TTCAACCCAG GACATACCAG GCGGGTGTGC AGCACAATGG GCAACTTCCA CTACAAGACC TTTGATGGAC AGGCTCTCTA CTTCCCTGGT

301 CTTCTGCAACT ATGTGTTCTC TGCACACTGT GGGGATGCCT ATGAGGACTT CAATATCCAG CTACGCCGTG TCCAGGAGTC TAATACCACC ACTCTGAGTA

401 GGGTCACCAT GAAGCTTGT GGCCTAGTTG TTGAGCTGAC CAAGAGCTCC GTCTTAGTCA ATAACCCCC GGTCCAGCTG CCCCITTAGCC AGTCTGGGGT

501 CCTCATTGAG CTCACGAATG GCTACCTGAA GGTGGTGGCT AGGCTGGGGC TGCTCTTCGT GTGGAACAGG GATGACAGTC TTCTGTGGA GTTGAGCACC

601 AAATATACCA ACAAGACTTG TGGTCTCTGT GGAGACTTCA ACGGCAGTCC AAAATCCAAC GAGTTCCTCT CCAACAATGT TAGGCTGACA CCCCTTGAGT

701 TTGGAACTT TCAGAAGATG GACGGCCCA CAGAGCAGT CCAAGACCCC CTTCCCTGTGC CCCAGAAGAA CTGCTCCGCC AGATCTGGTA TCTGTGAAAT

801 GATCCTAAAA GGTGAGCTGT TCTCAGGCTG TCGGCCCTGT GTGGACATCA GCAGCTACGT GGAGGCTTGC CGGCAGGACG TCTGTCTCTG TGAGAGCTTG

901 GACCCGCTG ACTGCATCTG CCATACCCTC GCTGAGTACT CCCGGCAGTG TGCACATGCT GGAGGGCAGC CCCAGGACTG CCGGGGCCCC AACCTCTGCT

1001 CCCAGACATG TCCCTCAAC ATGCAGCACC AGGAATGTTG CTCACCCTGT GTGGACACCT GCTCCAACCC CCAGCATTCC CAGTCTGTG AGGACCCTG

1101 TATTGCTGGC TGCTCTGTG CTGAGGGTAT GGTGCTTAT GACATTAATC AGATGGGGTG TGTTCCTGTG TCCAGTGTG CCTGCCTGTA CAATGGGACA

1201 CTTTATGCAC CCGGTACCAA TTACTTACT GACTGCACCA AGTGCACATG TTCTGGAGGC CAGTGGAGCT GCCAGGACAT CCCCCTGCCT GGCACCTGCT

1301 CAGTAATGGG AGGCTCCAC ATGTCCACAT TTGATGGAAG GCAATACACA GTACATGGGG AGTGCACCTA TGTGCTGAGC AAGCTTGTG ACAGTAATGC

1401 CTTCACTGTG CTGTTGAGC TGCGAAAGTG TGGACTGAC GAAAGTGAGA CTTGTCTGAA GACTGTGACA TTGAACCTGG GTGGGGGCA GACGGAGATC

1501 ATGGTAAAG CTACTGAGA GGTCTTTGT AACAGATCT ACACCCAGTT GCCAGTGTCT ACAGCCAATG CTACCTTCTT CCGGCCTTCA ACCTTCTCA

1601 TCGTTGGTGA GACCAACCTG GGTTCGAGC TTGAGATCCA GCTGAGTCCA ATTAGTCAAA CATCTGTGCG TCTGAAACCT GGGCTCAGGG GGCTAACCTG

1701 TGGGCTCTGT GGAACCTCA ACAGTATGCA GGCTGATGAC TTCCAGACTA TCAGTGGGGT TGTGGAGGGC ACAGCAGCTG CTTTCTTCAA CACCTTCAA

1801 ACTCAGGGCG CTTGTCCCAA TGTCAGAAT ATCTTTCAGG ACCCTGCTC GCTCAGCGTG GAGAATGAAA AGTATGCTCA CACTGGGTG TCTCTGCTGA

1901 CTAACGCCAG TGGTCCATTT TCCAGTGC CCGCCACCTG GAACCCAGC ACCTTCTCT CGAACTGCAT GTATGACACG TGCAACTGTG AGAAGAGCGA

2001 GGACTGCATG TGTGCAGCC TGCTCCTTA TGTGCTGCT TGTGCTGCA AAGGCGTCT GCTCAGTGC TGGAGGGATG GCATCTGCAC AAAGCTACA

2101 ATTACTGTG CCAAGTCAA GACCTATCAA TACCATATCA GCACCTGCCA GCCCACCCTG CTTGCTCTGA ATGAGAAAAG TGTCACCTGC CATGTACACT

2201 TCATCCCTGT AGATGGCTGC ACCTGCCCA AAGGCACCTT CTTAGATGAT TTGGGCAAA GTGTACAGGC TACCAGCTGT CTTTGTACT ACAAGGGATC

2301 CACAGTTCCC AATGGCGAGT CTGTGCAGGA CAGTGGGGCC ATTTGCACCT GCACCCAGG AGCATAACT TGTATTGGAG GTCTGCCCC GACTCCAGTG

2401 TGTGATGCAC CCATGATCTA TTTTACTGT CACAATGCCA CACCTGGTGA CACTGGAGCT GGATGTCAGA AGAGCTGTCA CACCCTAGAC ATGACCTGTT

2501 ATAGTCCGA GTGCGTGCCT GGCTGTGTG GCCCAATGG GCTGGTGGCA GATGAAATG GAGGCTGTGT TGTACTGAG GACTGTCTTT GTGTGCACAA

2601 TGAGGCCACC TATAGCCCTG GGGAGACCAT CCAAGTGGGA TGCAACAAC TGCACCTGTA GAACAGGATG TGGCAATGCA CAGACAAGCC TTGCCCTGGCC

2701 ACCTGTGCTG TGTATGGAGA TGGCCACTAC ATCACTTTTG ATGGGCAGCG CTACAGTTTC AATGGGGACT GCGAGTACAC ACTGCTACAG GACAACCTGT

2801 GTGGGAATGG CAGCTCCAG GATGCCTTC GTGTTATCAC TGAGAATC CCGTGGTA CTACAGGAAC CACTGCTCC AAGAGCATCA AGATCTCTCT

2901 GGGGAACAT GAGCTGAAGT TGAAGTACAG CAAGATGGAG GTGGTCCAGA AGGATGTGGG GCAAGGAGCC CTTACTTTG TCCACCAGT GGGCAACTAC

3001 CTGGTGGTG AAAGTGCAT TGGCCTGGT CTTTTGTTG ACAAGAAGAC TAGCATCTTT CTCAGACTCA GCCCTGAGTT CAAGGGCAGG GTCTGTGGCC

3101 TGTGTGGAA CTTTGTGAC AATGCCATCA ATGACTTAC CACACGAGC CAGTCCGTGG TCAAGTGCAT GTTGGAGTTT GGAATACTG GGAAGTTGTC

3201 TCCATCTGC CCGGATGTC TGGTGGCCAA GGACCCCTGC ACTGCCAACC CTTACCGCAA GTCTGGGCC CAAAAGCAAT GCAGCATCAT CAACAGCGAA

3301 ACTTCTCCG CTTGCCATGC TCATGTGGAG CCGCCAAGT ACTATGAAG TGTGTGAAT GACGCTGTG CTTGTACTC AGGGGGTGC TGGCAGTGT

3401 TCTGCACCAC TGTGGCCGCT TATGCCAGG CCTGCCATGA AGTGGGAGT TGTGTCTCT GGAGGACACC AGACATCTGC CCACTGTCT GTGACTACTA

3501 CAACCCAGAG GGTGAGTGT AGTGGCATA CCAGCCGTGT GGGGCCCTCT GCATGCTGAC CTGCCAAGC CTTACTGAC AGTGCCTACA AGATCTCCGT

3601 GGTCTGGAAG GATGCTATCC CAAGTGCCCA CCAACAGCCC CCATCTTTGA TGAGGGCACA ATGCAGTGTG TATCCAACCTG TACAGTACC TTCCCTGCC

3701 GCGTCAATGG AAAGTTGAC CGGCCAGGT CATCAGTACC TTCAGACAAA AACTGCGATT CTTGCATCTG CACGGAGAGT GGTGTGCGCT GTACCCACAA

3801 TGCTGGTGC TGTGCTGTA CCTACAAGG GCAACAGTTC CATCTGGG AGATCATCTA CCACACAACA GATGGCATAG GAGGCTGCAT CTCTGCACAC

3901 TGACGGGCC ATGGTACCAT CGAGAGGAGC GTTGACACT GCAACTCCAC CACCCTACA CCCCCACCA CTTTCTCTT CCCCACAGC CCGCTCATGA

4001 CCTCAATGCA ACCCTCCAGC ACACATTCCA GCCCTACCCC GAGTGTAGGG TCCTCAGGGG CCTCAAGCAA GGCTGCATCG ACAACCAGCA GCATATTGTC

4101 TGTGAAGAGC CCTGTTACG CTCCTATGAC CATGTCTACT TCAGCCTCCG CCGTAACCAC ATCAGGTTGC CCGGAGGAGT GCTCTGGTCT **TCCTGGATG**

4201 **GATGTTA**GCC GTCCTGGAGC TGGCATTGAC AGTGGTACT TTGACACTCT GGAGAACCCT CCGTCCCATG GCTACCCAAT CTGCCAAGTG CCAAAGCAGC

4301 TAGAGTCCG TGCTGAGGCT AGCCCCGGG TGCCCTTCTC CGAGCTGCAG CAGCACCTGG AGTGTAGCAC AACAGTGGG CTGATCTGTT ACAACAGTGA

4401 TCAGCTGTCA GGGCTCTGTG ACAACTACCA GATCAAAGTC CAGTCTGTGA CCCCCTCAG CTGTCCAACC TCCCAGCAGCA CCCATGTGAT **ATCCGGCGCC**

4501 **GCCATGTGA GCAAGGGCA GGAGCTGTT ACCGGGGTGG TGCCATCTCT GGTGAGCTG GACGGCAGC TAAACGGCCA CAAGTTCAGC GTGTCCGGCC**


Fig. S1. (Continued)

4701 CTACGGCGTG CAGTGCTTCA GCCGCTACCC CGACCACATG AAGCAGCAGC ACTTCTTCAA GTCCGCCATG CCCGAAGGCT ACGTCCAGGA GCGCACCATC  
 4801 TTCTTCAAGG ACGACGGCAA CTACAAGACC CGCGCCGAGG TGAAGTTCGA GGCGACACC CTGGTGAACC GCATCGAGCT GAAGGGCATC GACTTCAAGG  
 4901 AGGACGGCAA CATCCTGGGG CACAAGCTGG AGTACAACCTA CAACAGCCAC AACGTCTATA TCATGGCCGA CAAGCAGAAG AACGCATCA AGGTGAACCT  
 5001 CAAGATCCGC CACAACATCG AGGACGGCAG CGTGCACTGC GCCGACCACT ACCAGCAGAA CACCCCATC GCGCAGGGCC CCGTGTGCT GCCCGACAAC  
 5101 CACTACCTGA GCACCCAGTC CGCCCTGAGC AAAGACCCCA ACGAGAAGCG CGATCACATG GTCTGTGG AGTTGTGAC CGCCGCCGGG ATCACTCTCG  
 5201 GCATGGACGA GCTGTACAAG AAAGGGGCGG CGATATCATC CTCCAGGACG ACTAATTTGG ATAAACACAAC CTCCTCAGTC CCTGTTACCT CAACACCCCA  
 5301 TACCAGTCA CCCAATACAG GAAAGACCAG CACCATCTCT ACAACCCAAA CCAGCTCA CC CAATACAGGA AAGGCCAGCA CCCCATCAAC ACCCAAAACC  
 5401 AGTCAACCA ATACAGGAAA GACCAGCACC ATCTCTACAA CCCAAACCAG CTCACCCAAT ACAGGAAAGG GCAGCACCCC CTCACACCC CAACCCAGCT  
 5501 CACCAATAC AGGAAAGACC AGCACCACCT CTACAACCCA AACCCAGTCA CCCAATACAG GAAAGGCCAG CACCATCTCT ACAACCCAAA CTATCTCAAC  
 5601 CTCAGGGTCC ACCATGCCTT CCTCTGAAAC AACTCATGAG TGCAAAACAGG AGCTTTGCAA TTGACCAAT TGGCTAGATG GCAGTTACCC TGGGTCTGGC  
 5701 AGAAACAGTG GAGATTTTGA CACCTTTGTG AACCTGAGAT CCAAAGGATA CAAGTCTGT GAGAAGCCAC GAAATGTTGA GTGCAGGGCT CAGTCTTTTC  
 5801 CCAACACACC ACTGGAGGAG CTGGGGCAGA ATGTGACCTG CAGCCGAGAG GAGGGTTTGA TCTGTTTGA CAAGAACCAG CTGCCACCCA TGTGCTACAA  
 5901 CTATGAGATC CGGATTGAGT GCTGCACAGT GGTAACAAC TGTTCCACAG CTTCACTTAC CACACATCCC ACCTCACATG GAGTCAGCA GAAAACAGAG  
 6001 ACCAACTGGA CCACCATGT GTATTCTCT CCCACAAAAG ACACCAGTAG TCACTCAGCA ACCATAGACA CAAAGACCTG GACCTCAGGT ATTTACACA  
 6101 CAACCACTCA ACCAGTGACC ACCCACTGCC AGCTACAGTG CAACTGGACC AAGTGTTTGA ACCTGACTT CCCAGTGTCC GGGCCACATG GAGGGGACCT  
 6201 GGAAACCTAT AGCAACATTG AGAGGAGCGG AGAGAGACTC TGTCACCGAG AGGAGATCAC ACAGTTGCAA TGCAGGGCTA AGAACTACCC TGAGAGAGAG  
 6301 ATGGAGGATC TGGGTACAGT GGTGAAGTGT GACCCCACTG TGGGCTGGT GTGCAACAAC AGGACCAGG GGGGCGACTC TGGGATGTGC TCAACTATG  
 6401 AGGTGCGACT GCTGTGCTGT CACATTCCTG AAGACTGCCC CAGGACTGAT CAGACTTCTC CTGTGACATT ATCCATAAG CCCTCATCTG CAGTTGTGTC  
 6501 ACCATCATCT GTGTCCCGT CCTTGTGAC CAGCCATAGG GTTCACTCTA CCACTCCCTG CTTCTGACG GTGTACAGCC AGCTATACCC CTTGGGATCC  
 6601 ATCATCTACA ACCAGACAGA CCTTGATGCG CACTGTTACT ATGCGATGTG TAGCCAGGAT TGTCAGGTGG TCAAGAGGGT TAGTCAAGC TGCCCTCCA  
 6701 CCATGCCACC CCCTGCGACA ACTCTATCTA CATCTACCAC GCCACCTGTC ACTGGGCGGG ATCGGTGCAA TGTGTTTCT CCAAGACTGA GAGGAGAGAC  
 6801 CTGGCCAATG CCGAATTGTT CCAAGCCAC CTGTGAGGGC AACAATGTCA TCTCTTGTG CCCACGCCAG TGCCAGAGC TGAATGAACC ATCTGTGCC  
 6901 AATGTTTACC CACCTCTGAA GGTGGATGAC CAGGATGTT GCTGCCAGCA CTACCAGTGC CAATGTGTT GCAGCGGGTG GGGTATCCC CACTACATCA  
 7001 CATTGATGG CACCTACTAC ACTTCTCTG ATAAGTGCAC ATACGTGCTG GTGCAGCAGA TCGTGCCCGT GTTTGGATC TTCCGTGTGC TCATTGACAA  
 7101 CTACTACTGT GACGTGGAG ACAGCTCTC CTGCCACAG TCCATCATTG TGGAGTACCA CCAGGACCGT GTGGTGTGA CCCGACGGC AGTTAGCGGG  
 7201 GTCATGACCA ACCAGATCAT CTTCAACAAC AAAGTAGTCA GTCCTGGCTT CCAGCAGAAT GGCATTGTCA CCTCCCGTGT GGGTATCAAG ATGTATGTTA  
 7301 CCATCCAAGA GATTGGTGC CGGGTATGT TTTAGGTTT CATCTTCTCC GTCAGGTTGC CTTTCAACTT GTTGCCAAAC AACACAGAGG GCCAGTGGCG  
 7401 CACTTGACC AATGACAAAA AGGATGAGTG CCGCTCGCT GGGGGTTCCA TAGCCTCTC TTGTTCTGAG ATGTCCCTCC ACTGGAAGGT GCCCAACCAG  
 7501 CCTTCTGCC AAGGGCTCC ACCAACTCCA ACTTCAGTGG TACCCAGGCC TTCACCTACT CCGTGCCAC CATCGCCACT CTGTGAGTC ATCCTAAGCA  
 7601 ATACCTTCAA GCTCTGCCAT GACGTCATCC CCCCCTGCA GTTCTATCAA GGCTGTTAT TTGACTACTG CCACATGCTG GACCTGGAGG TTGTATGCTC  
 7701 AGGCCTAGAG CTCTATGCAT CACTCTGTGC AGCCCAAGGC GTGTGCATC CCTGGAGAAG CCAAACCAAC AACACCTGCT CATTACAGTG CCCTGATAAC  
 7801 CAAGTATACC AGCCTTGTG CCCATCCAAC CCTCACTACT GCTACAGGGA TGATAGCATC AGCCCAAGCC TGACCCTTCA AGAGGCTGGT CCCAAGACAG  
 7901 AGGGCTGCT CTGTCCAGAC AGCACGACAC TTTTCAGTAC CAATGACTCA ATCTGCGTGC CTTCTGCCA ATGGTGTCTG GGGCCTCGT GGGAGCCTGT  
 8001 GGAGCCGGGT CACACCATA GCATCGACTG CCAGGACTGC ATCTGTAAGG AAGCCACGCT AACCTGCCAA AAGAAGGCCCT GTCCTCAGCC CACCTGTCCA  
 8101 GAGCCTGGCT TTGTGCCAGT GCCTGTAGCC CTGGAGGCTG GCCAATGTTG TCCCCAGTTC AGCTGTGCC GAACTCCAG CCACTGCCCT CCGCTCTGC  
 8201 ACTGCCCGAA GAATTCTAGC CTGATAGTCA CATAAGAGGA GGGAGCTTGC TGCCGACCC AGAACTGCAG CAGTCAGAAG GGCTGTGAAG TCAACGGGAC  
 8301 TCTTACCAG CCTGGTACG TGGTCTCTC CAGCCTATGT GAGAGATGCC TGTGTGAGT TCCAGCAAT CCCCTTCCG ATGTCTTAT GGTGAGTGT  
 8401 GAGACTGAGC TGTGAACAC CCAGTGTCT AAGGGCTCTG AGTACCAGGC CATGCCAGG CAGTGTGTG GCAAGTGTAT ACCGAAGACC TGCCCTTTTA  
 8501 AAAACAACAG TGGTTCTACC TACTTCTACC AGCCTGGTGA GTTATGGGCA GAACCTGGGA ACCCGTGTGT GACTCATAAG TGTGAGAAAT TCCAAGATG  
 8601 ACTCATGGTC GTGACAATGA AGACAGAGTG TCCCAAGATC AACTGTCCGC AGGGCCAGGC TCAGCTGAGA GAAGACGGAT GCTGTATGA CTGTCCCTTA  
 8701 CCTAACCAGC AGAAATGTAC GGTGCACCAA AGACAGCAGA TCATCCGTCA GCAAACTGC AGCTGTGAG GCCCAGTGA CATCTCTAC TGCCAAGGCA  
 8801 ACTGCGGGGA CAGCATCTCC ATGACTCCC TGGAGGCCAA CAAGGTAGAG CACACATGTG AGTGTGCCA GGAGCTGCAA ACCTCTCAGA GGAATGTGAC  
 8901 TCTGCGTGC GATGATGGCT CCAGTCAGAC CTTCACTAC ACCCAGTTG AGAAGTGTG CTGCCTGGC CAGCAGTGC ATGCTTTAGG GGACACAAGC  
 9001 CATGCAGAGT CCTCAGAACA AGAGTTCAAG TCCAAGGAAA GTGAGGAACA TGGCCAGCAG TTGGCATTCA GGTGACGCA GGACATGCT GGCCTTTCC  
 9101 AGTAAACT


**Fig. S1.** Muc5ac-GFP cDNA cloning strategy and sequence. Shown are primer map and sequences used to clone Muc5ac cDNA. Primers (shown as arrows) were designed from the reconstructed Muc5ac cDNA sequence. Lines below primers characterize the three clones obtained by high-fidelity PCR. Dotted line shows a region with high variability. Unique restriction sites (NheI, SalI, and EcoRV) were used for clone assembly. Muc5ac cDNA sequence that was cloned and overexpressed in mice is shown with start and stop codons in red, GFP tag in green, and primer location in blue. Quantitative PCR primers are underlined.








**Fig. S6.** Native GFP fluorescence from frozen Muc5ac-Tg and WT lung sections. Shown is confocal imaging of native GFP signal captured from Muc5ac-Tg (A, *i*) and WT (B, *i*) frozen sections, stained with DAPI for nuclear labeling. Cross-sections of mouse airways and parenchyma are shown. Overlaid GFP/DIC/DAPI images are displayed for Muc5ac-Tg (A, *ii*) and WT (B, *ii*) mice.




**Fig. S7.** Muc5ac-/GFP-positive layer lining the epithelial surfaces of Muc5ac-Tg mouse trachea. Longitudinal sections of Muc5ac-Tg trachea were stained with (A) a goat anti-GFP and (B) the rabbit anti-Muc5ac antibody (UNC294), which revealed an irregular mucus blanket coating the epithelial surfaces of Muc5ac-Tg animals. C shows the overlay of signals with DIC.




**Fig. S8.** Immunohistochemical detection of a Muc5ac layer lining the large airways of Muc5ac-Tg but not WT mice. Cross-sections of fixed WT and Muc5ac-Tg lungs were stained with the rabbit anti-Muc5ac and a goat anti-CCSP antibody. CCSP labeled all airways. Whereas Muc5ac was not detected in WT mice, a positive Muc5ac signal was detected lining the large airways of Muc5ac-Tg animals.





**Fig. S9.** Electron microscopy images illustrating the mucus layers observed in Muc5ac-Tg vs. WT animals. Lungs were fixed with perfluorocarbon-OsO<sub>4</sub>, sectioned at the midsection of the lobes. (A and B) Richardson's stain of WT (A) and Muc5ac-Tg (B) intermediate-size airways. (C and D) Electron microscopy images of selected airways that showed sporadic mucus patches in WT mice (C) and revealed the presence of a "thicker" mucus layer in Muc5ac-Tg mice (D). Images are representative of three animals from each genotype.



**Fig. S10.** Neuraminidase treatment of Muc5ac-Tg BALF restores PR8 infectivity in vitro. BSA or Muc5ac-Tg BALF was treated with neuraminidase (150 milliunits/mL) for 1 h to remove the terminal sialic acids. Neuraminidase was deactivated by heat (60 °C for 5 min) before incubation with PR8 virus ( $10^4$  pfu/mL solution). (A) Neuraminidase treatment showed no effect with BSA control (i). However, treatment of BALF (~1 mg/mL) with neuraminidase restored PR8 infectivity (ii). Values are means  $\pm$  SEM, \* $P < 0.005$  ( $n = 3$ ). These results suggest that sialic acids are, at least in part, responsible for the decreased infection observed with Muc5ac-Tg BALF. (B) Confirmation of effectiveness neuraminidase treatment via mucin agarose gel on reduced Muc5ac-Tg BALF. GFP signal (i) showed a delayed migration of Muc5ac-GFP in treated BALF compared with untreated BALF, which concurs with the removal of negative charges associated with sialic acids.  $\alpha$ 2,3 lectin-binding signal (ii) was greatly reduced in treated BALF.